Free Trial

Gyre Therapeutics (NASDAQ:GYRE) Sees Unusually-High Trading Volume - Still a Buy?

Gyre Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) saw an uptick in trading volume on Monday. Approximately 124,635 shares changed hands during trading, an increase of 14% from the average daily volume of 109,507 shares. The stock last traded at $4.76 and had previously closed at $4.31.

Analyst Upgrades and Downgrades

Several brokerages have commented on GYRE. Weiss Ratings restated a "sell (d-)" rating on shares of Gyre Therapeutics in a research note on Wednesday, November 4th. Zacks Research upgraded Gyre Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Tuesday, October 6th. Finally, Wall Street Zen raised shares of Gyre Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, November 7th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Reduce".

Get Our Latest Stock Analysis on GYRE

Gyre Therapeutics Stock Performance

The stock has a market capitalization of $547.77 million, a PE ratio of -23.60 and a beta of 2.14. The business's 50-day moving average price is $6.30 and its 200 day moving average price is $6.81.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.19. Gyre Therapeutics had a negative return on equity of 7.39% and a negative net margin of 14.80%. The company had revenue of $32.93 million for the quarter, compared to the consensus estimate of $28.40 million. As a group, equities research analysts predict that Gyre Therapeutics, Inc. will post -0.61 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in shares of Gyre Therapeutics during the second quarter worth approximately $6,550,000. Bank of New York Mellon Corp bought a new position in shares of Gyre Therapeutics during the 2nd quarter valued at $414,000. Deutsche Bank AG bought a new position in shares of Gyre Therapeutics during the 2nd quarter valued at $118,000. Dimensional Fund Advisors LP grew its holdings in shares of Gyre Therapeutics by 131.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company's stock valued at $176,000 after purchasing an additional 14,365 shares during the last quarter. Finally, Bank of America Corp DE purchased a new position in Gyre Therapeutics in the 2nd quarter worth $83,000. 23.99% of the stock is currently owned by institutional investors.

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals. Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Gyre Therapeutics Right Now?

Before you consider Gyre Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.

While Gyre Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines